Lion TCR Pte. Ltd.
TCR-T(Lion TCR Pte. Ltd.)은 Chronic Hepatitis B 표적 세포·유전자 치료로, Chronic Hepatitis B 영역에서 개발·상용화 중입니다. 작용기전: CAR-T), natural killer (NK) cells, and other emerging cellular therapies such as TCR-T, cytokine-induced killer (CIK) cells, and γδ T cells-in the context of ovarian ca. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 50% (ClinicalTrials.gov NCT05943990). 차별점: novel cytokine cocktail (CKT) containing IL-2, IL-7, IL-15, and TGF-β.
Chronic Hepatitis B
Chronic Hepatitis B
Active
NK cell recognition via the "missing-self" response
retrovirally transduced to express KRAS G12D-targeting TCRs, and expanded for 10 days in t
humanized patient-derived xenograft model of Claudin18
novel cytokine cocktail (CKT) containing IL-2, IL-7, IL-15, and TGF-β
CAR-T), natural killer (NK) cells, and other emerging cellular therapies such as TCR-T, cytokine-induced killer (CIK) cells, and γδ T cells-in the context of ovarian cancer
cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are critically evaluated
biomarkers, tumor microenvironment profiling, and personalized treatment selection is explored as a means to
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Lion TCR Pte. Ltd.
TCR-T(Lion TCR Pte. Ltd.)은 Chronic Hepatitis B 표적 세포·유전자 치료로, Chronic Hepatitis B 영역에서 개발·상용화 중입니다. 작용기전: CAR-T), natural killer (NK) cells, and other emerging cellular therapies such as TCR-T, cytokine-induced killer (CIK) cells, and γδ T cells-in the context of ovarian ca. Phase 1 안전성·PK 탐색 단계입니다. 대표 임상 효능: ORR 50% (ClinicalTrials.gov NCT05943990). 차별점: novel cytokine cocktail (CKT) containing IL-2, IL-7, IL-15, and TGF-β.
Chronic Hepatitis B
Chronic Hepatitis B
Active
NK cell recognition via the "missing-self" response
retrovirally transduced to express KRAS G12D-targeting TCRs, and expanded for 10 days in t
humanized patient-derived xenograft model of Claudin18
novel cytokine cocktail (CKT) containing IL-2, IL-7, IL-15, and TGF-β
CAR-T), natural killer (NK) cells, and other emerging cellular therapies such as TCR-T, cytokine-induced killer (CIK) cells, and γδ T cells-in the context of ovarian cancer
cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome are critically evaluated
biomarkers, tumor microenvironment profiling, and personalized treatment selection is explored as a means to
resistance to dominant suppressive pathways such as TGF-β and adenosine signalling, improved trafficking and tissue penetration
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.